Discontinuation of Lemborexant and Daridorexant
Both lemborexant and daridorexant can be stopped abruptly without a mandatory waiting period or tapering schedule, as neither medication requires gradual discontinuation. This represents a significant advantage over benzodiazepine receptor agonists (BZRAs) and distinguishes dual orexin receptor antagonists (DORAs) from older insomnia medications.
Key Pharmacokinetic Considerations
Daridorexant
- Half-life: approximately 8 hours 1
- Drug effects decrease by ~50% at 12-18 hours after the last dose
- Trough levels reach ~25% of steady state by 24 hours (in patients with normal renal function)
- No accumulation occurs with repeated dosing 1
- No withdrawal symptoms, rebound insomnia, or physiological tolerance have been documented 2
Lemborexant
- Similar favorable discontinuation profile to daridorexant
- No evidence of withdrawal symptoms or rebound insomnia with abrupt discontinuation 2
- Does not require special deprescribing protocols 3
Clinical Evidence for Abrupt Discontinuation
The most robust evidence comes from a 40-week extension study of daridorexant that included a 7-day placebo run-out period. After up to 12 months of continuous treatment, patients who abruptly stopped daridorexant showed:
- No withdrawal-related symptoms 4
- No rebound insomnia 4
- No next-morning sleepiness during the discontinuation phase 4
This contrasts sharply with BZRAs (benzodiazepines and Z-drugs), which require gradual tapering with dose reductions of 10-25% each week to avoid withdrawal symptoms 3.
Practical Discontinuation Approach
For both medications, simply stop the medication when clinically indicated—no waiting period or dose reduction is necessary. This applies whether the patient has been on treatment for weeks or months 3, 4.
When to Consider Stopping
- Treatment goals achieved (sustained improvement in sleep and daytime functioning)
- Adverse effects outweigh benefits
- Patient preference
- Transition to non-pharmacological therapy (e.g., CBT-I)
Important Caveats
Monitor patients for return of insomnia symptoms after discontinuation, but this represents recurrence of the underlying condition rather than withdrawal or rebound. The distinction is critical:
- Withdrawal/rebound: New or worsened symptoms beyond baseline that emerge within days of stopping
- Recurrence: Gradual return to baseline insomnia symptoms over weeks
The European consensus guidelines explicitly state that daridorexant and melatonin 2 mg PR do not require special switching or deprescribing protocols, unlike BZRAs which necessitate complex cross-tapering strategies 3.
Switching Between DORAs
If switching from one DORA to another (e.g., lemborexant to daridorexant or vice versa), direct substitution is appropriate without overlap or gap periods 3. The shared mechanism of action (orexin receptor antagonism) and absence of withdrawal phenomena support immediate switching.
This straightforward discontinuation profile represents a major clinical advantage, particularly for elderly patients who may be on multiple medications and for whom complex tapering schedules pose adherence challenges 5.